ArQule Posts Narrower-than-Expected Q1 Loss
moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
ARQL
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
Q1 2014 ArQule, Inc. Earnings Release – 07:00 am ET
moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
ArQule Reports First Quarter 2014 Financial Results
[Business Wire] – ArQule, Inc. today announced its financial results for the first quarter of 2014. moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
ArQule to Report Fiscal 2013 Financial Results on March 5, 2014
[Business Wire] – ArQule, Inc. today announced that it will report its financial results for the fiscal 2013 year-end and fourth quarter on Wednesday, March 5, 2014 at 7:00 a.m. eastern time. moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
ArQule, Inc. to Present at RBC Capital Markets Healthcare Conference
[Business Wire] – ArQule, Inc. today announced that the Company will present at the 2014 RBC Capital Markets Healthcare Conference on Tuesday, February 25, 2014 at 10:30 a.m. The pres moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib
[Business Wire] – TOKYO & WOBURN, Mass.–(BUSINESSWIRE)– Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC … moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
DAIICHI SANKYO AND ARQULE ANNOUNCE TOP-LINE RESULTS OF PHASE 2 TRIAL WITH TIVANTINIB IN COLORECTAL CANCER
[at noodls] – For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address … moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer
[Business Wire] – TOKYO & WOBURN, Mass.–(BUSINESSWIRE)– Daiichi Sankyo Company, Limited (TSE 4568) and ArQule, Inc. (Nasdaq: ARQL) today announced the top-line results of a randomized Phase 2 signal generation trial of … moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboardSee who ArQule is hiring next, click here to view […]
PropThink: ArQule Reports 3Q Results as Investors Now Look to Tivantinib’s HCC Indication
[ACN Newswire] – By Jake KingOncology-focused ArQule, Inc. (NASDAQ:ARQL) reported third quarter financial results on Thursday morning, noting that cash, equivalents, and marketable investts totaled $140M on Sept. 30, and … moreView todays social media effects on ARQLView the latest stocks trending across Twitter. Click to view dashboard […]
